Ironically I think from a value and commercial perspective, the MND line has the best shot, due soley to the MND foundation.
They will not only keep PAA held to account to deliver, they will then drive any possible next stage also. Scrutiny and accountability are wonderful things in business, it's just a shame that PAA don't feel this same sense of obligation to shareholders.
Clinical Trials Interview June 2022, page-17
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $85.73K | 407.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53482 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 278844 | 4 |
View Market Depth
| Last trade - 15.15pm 19/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |